Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
Salvador Payán Pernía, Member of the Board of Directors of the Erythropathology Group at Spanish Society of Hematology and Hemotherapy (SEHH), shared on LinkedIn about a recent article he and his colleagues co-authord, published in Emerging Therapeutic, adding:
“The pathophysiology of Sickle Cell Disease (SCD) is so multifaceted, and the heterogeneity of patients’ complication profiles so great, that the path toward optimal pharmacological treatment will likely involve combining different therapies and tailoring treatment to each patient’s individual profile—a profile that we still need to characterize better than we currently can.
The results of the RISE UP study firmly establish mitapivat as a treatment for anemia, one of the defining features of SCD, which can have a substantial negative impact even in patients who do not experience recurrent vaso-occlusive crises.
In this editorial commentary, my colleagues and friends at CIEMAT, José Carlos Segovia Sanz and Isabel Ojeda Pérez, and I reflect on some of the findings from the RISE UP study and discuss what they may mean for the therapeutic positioning of mitapivat in SCD.”
Title: Mitapivat in sickle cell disease: a therapeutic setback or a shift in perspective?
Authors: Salvador Payán-Pernía, Isabel Ojeda-Pérez, Jose-Carlos Seg
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 12, 2026, 17:39Annie Bauzon: Differentiating Direct and Indirect Coombs Tests in Hematology
-
Oct 12, 2026, 17:15Cedric Hermans: Identifying and Diagnosing Hemophilia Carriers and Affected Females
-
Oct 12, 2026, 17:01Bianca Rocca: Evaluating Factor XI Inhibition Lessons from LIBREXIA-ACS
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026